Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Rajesh Samannan

Internal Medicine Oklahoma City, OK Medical Doctor

NPI 1518375302 CMS profile 406272

1200 Childrens Ave, Oucp 14000 A2, Oklahoma City, OK 73104

Open in the dashboard

General payments

$3,924

40 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rajesh Samannan of Oklahoma City, OK is reported in the CMS Open Payments database as having received $3,924 across 40 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $398 7
2024 General $217 5
2023 General $1,878 14
2022 General $1,375 10
2021 General $57 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rajesh Samannan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Rajesh Samannan were reported at $398. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Rajesh Samannan Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $57 $135 $37–$521 $132
2022 $1,375 $141 $42–$496 $149
2023 $1,878 $149 $45–$519 $160
2024 $217 $154 $47–$537 $164
2025 $398 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Olympus Corporation of the Americas $3,122 23 payments
  2. Genzyme Corporation $394 8 payments
  3. Stryker Corporation $164 1 payment
  4. Sanofi-Aventis U.S. LLC $93 1 payment
  5. Abiomed $54 2 payments
  6. Intuitive Surgical, Inc. $40 1 payment
  7. Regeneron Healthcare Solutions, Inc. $23 1 payment
  8. United Therapeutics Corporation $21 2 payments
  9. GlaxoSmithKline, LLC. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $3,042 20 payments
  2. Food and Beverage $789 19 payments
  3. Education $93 1 payment
Products named General payments · program years 2021–2025
  1. SINGLE USE SUCTION VALVE (Sterile) $3,122 23 payments
  2. DUPIXENT Immunology $487 9 payments
  3. FLOWTRIEVER $164 1 payment
  4. Da Vinci Surgical System $40 1 payment
  5. DUPIXENT Inflammation And Immunology $23 1 payment
  6. TYVASO $13 1 payment
  7. NUCALA $12 1 payment
  8. ORENITRAM $8 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

580

Median for Critical Care (Intensivists): 406

Drug cost

$157,757

Median for Critical Care (Intensivists): $197,260

Branded share of claims

72.9%

Median for Critical Care (Intensivists): 69%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 39 $41,835
Spiriva Respimat Tiotropium Bromide Brand 29 $21,302
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 20 $12,950
Incruse Ellipta Umeclidinium Bromide Brand 30 $12,641
Symbicort Budesonide/Formoterol Fumarate Brand 39 $10,538
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 11 $9,809
Spiriva Handihaler Tiotropium Bromide Brand 13 $9,649
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 16 $8,504
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 32 $6,510
Advair Hfa Fluticasone Propion/Salmeterol Brand 11 $4,884

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,531 Part D prescribers listed as Critical Care (Intensivists); they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$30,588

Medicare's payments for the services billed

Medicare patients

156

Average age 76

Services billed

289

66 women, 90 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 49%
Heart failure 44%
Ischemic heart disease 43%
Arthritis 38%
Diabetes 35%
Atrial fibrillation 35%
Chronic kidney disease 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $217
$217 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

40 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record